Lee LJ, et al. - Using data from national claims databases (2012–2016) in the United States, researchers compared smoking-attributable (SA) and all-cause health-care costs among smokers who were prescribed varenicline (VAR) vs a commonly used nicotine-replacement therapy patch (NRT-P). For up to 1 year on a quarterly basis, adults initiating VAR or NRT-P without use of any other smoking-cessation products were followed. Findings revealed that lower SA and all-cause medical costs related to the use of VAR vs NRT-P resulted in savings in all-cause total costs and potentially offset the high pharmacy costs of VAR among adherent patients.